Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in ...

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...

Curocell launches Limcato, South Koreas first domestic CAR-T cancer therapy Curocell introduces first local CAR-T therapy, ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

The Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few months after it was given the okay south of the border. Yescarta ...

Galapagos' CAR-T therapy GLPG5101 shows promising efficacy but has limited durability data and small patient samples compared to Yescarta. Phase 1 safety concerns have improved in Phase 2 ...

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novartis ...

This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape.Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - ...

However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is under pressure due to competitive headwinds, which are expected to continue in 2025. Breast cancer drug Trodelvy has ...

This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, ...